Solstice Oncology Partner, Hepo Pharmaceuticals, Completes $225 Million Series A Funding to Accelerate Prusabide Monoclonal Antibody in New Adjuvant Cancer Immunotherapy
September 10, 2026 — 00:40 CST
This Data Is Locked!
This area is available only to Subscribers.
Hepo Pharmaceuticals announced that its partner, Solstice Oncology, has successfully raised $225 million in Series A funding to advance the second-generation Fc-enhanced CTLA-4 antibody, Prusabide... [DATA LOCKED]
UNLOCK DATA
Follow the Money & Subscribe for Access to the Best Data and Intelligence on Chinese Venture Capital Deals
